Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection

NCT07135349 is registered in ClinicalTrials.gov with Shanghai Argo Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07135349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07135349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection
Lead sponsor
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 2, 2025
Completion date
May 8, 2028
Enrollment
209 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b